Applying transcriptomic and proteomic knowledge to Parkinson's disease drug discovery

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Expert Opinion on Drug Discovery

• Publication date

  2007-08-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/17460441.2.9.1225PMID 23496130
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.

  2007cited by this paper
• Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies

  2007cited by this paper
• Molecular markers of early Parkinson's disease based on gene expression in blood

  2007cited by this paper
• Iron and α-synuclein in the substantia nigra of MPTP-treated mice

  2007cited by this paper
• Green tea polyphenol (–)‐epigallocatechin‐3‐gallate promotes the rapid protein kinase C‐ and proteasome‐mediated degradation of Bad: implications for neuroprotection

  2007cited by this paper
• Therapeutic targets and potential of the novel brain‐ permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease 1

  2007cited by this paper
• The 5′-untranslated region of Parkinson's disease α-synuclein messengerRNA contains a predicted iron responsive element

  2007cited by this paper
• Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.

  2007cited by this paper
• Rasagiline improves quality of life in patients with early Parkinson's disease

  2006cited by this paper
• Mechanisms of action of green tea catechins, with a focus on ischemia-induced neurodegeneration.

  2006cited by this paper
• Iron chelation in the biological activity of curcumin.

  2006cited by this paper
• Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies.

  2006cited by this paper
• Fruit and vegetable juices and Alzheimer's disease: the Kame Project.

  2006cited by this paper
• Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease

  2006influential reference
• Evaluating the comparability of gene expression in blood and brain

  2006cited by this paper
• Reduction of iron‐regulated amyloid precursor protein and β‐amyloid peptide by (–)‐epigallocatechin‐3‐gallate in cell cultures: implications for iron chelation in Alzheimer's disease

  2006cited by this paper
• Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.

  2006cited by this paper
• In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of substantia nigra damage

  2006cited by this paper
• Pathology associated with sporadic Parkinson's disease--where does it end?

  2006cited by this paper
• Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease

  2006influential reference
• Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory

  2006cited by this paper
• Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil

  2006cited by this paper
• Multifunctional drugs with different CNS targets for neuropsychiatric disorders

  2006cited by this paper
• Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease.

  2006influential reference
• Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1.

  2006cited by this paper
• A network dysfunction perspective on neurodegenerative diseases

  2006cited by this paper
• Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate.

  2006cited by this paper
• Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells.

  2005cited by this paper
• Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

  2005cited by this paper
• Green tea polyphenol (–)‐epigallocatechin‐3‐gallate induces neurorescue of long‐term serum‐deprived PC12 cells and promotes neurite outgrowth

  2005influential reference
• Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms

  2005influential reference
• Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion

  2005cited by this paper
• Epigallocatechin gallate inhibits HIF-1α degradation in prostate cancer cells

  2005cited by this paper
• Multifunctional Activities of Green Tea Catechins in Neuroprotection

  2005influential reference
• A potential role of the curry spice curcumin in Alzheimer's disease.

  2005cited by this paper
• Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.

  2005influential reference
• Regulation of Bcl‐2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine

  2005cited by this paper
• Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice

  2005cited by this paper
• Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds.

  2005cited by this paper
• Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia

  2005cited by this paper
• Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition

  2005cited by this paper
• Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

  2005cited by this paper
• Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.

  2005cited by this paper
• Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment

  2004cited by this paper
• A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation.

  2004cited by this paper
• Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-κB Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis1

  2004cited by this paper
• A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

  2004cited by this paper
• A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis.

  2004cited by this paper
• Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.

  2004cited by this paper
• Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts.

  2004cited by this paper
• Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats.

  2004cited by this paper
• Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.

  2004cited by this paper
• N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor

  2004cited by this paper
• Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes

  2004cited by this paper
• Proteomic approach to studying parkinson’s disease

  2004cited by this paper
• Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease.

  2004cited by this paper
• Iron, brain ageing and neurodegenerative disorders

  2004cited by this paper
• Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models

  2004cited by this paper
• N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor.

  2004cited by this paper
• Epigallocatechin‐3‐gallate inhibits STAT‐1 activation and protects cardiac myocytes from ischemia/reperfusion‐ induced apoptosis

  2004cited by this paper
• Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members

  2004cited by this paper
• Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate.

  2003cited by this paper
• Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

  2003cited by this paper
• Neuroprotective agents for clinical trials in Parkinson’s disease

  2003cited by this paper
• Tea Catechins and Polyphenols: Health Effects, Metabolism, and Antioxidant Functions

  2003cited by this paper
• Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor.

  2003cited by this paper
• Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury.

  2003cited by this paper
• Neuroprotection and neurorescue against Aβ toxicity and PKC‐dependent release of non‐amyloidogenic soluble precursor protein by green tea polyphenol (‐)‐epigallocatechin‐3‐gallate

  2003cited by this paper
• Parkinson's Disease Mechanisms and Models

  2003cited by this paper
• cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells

  2003cited by this paper
• The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

  2002cited by this paper
• Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake.

  2002cited by this paper
• An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript*

  2002cited by this paper
• MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide.

  2002cited by this paper
• Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells.

  2002cited by this paper
• Recent developments in the pathology of Parkinson's disease.

  2002cited by this paper
• The dementias.

  2002cited by this paper
• Mitochondrial permeability transition mediates apoptosis induced by N‐methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl‐2 and rasagiline, N‐propargyl‐1(R)‐aminoindan

  2002cited by this paper
• Involvement of Protein Kinase C Activation and Cell Survival/ Cell Cycle Genes in Green Tea Polyphenol (−)-Epigallocatechin 3-Gallate Neuroprotective Action*

  2002influential reference
• An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells.

  2002cited by this paper
• C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

  2001cited by this paper
• Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

  2001cited by this paper
• Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

  2001cited by this paper
• alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro.

  2001cited by this paper
• Effects of pH and Metal Ions on Antioxidative Activities of Catechins

  2001cited by this paper
• Transfection‐enforced Bcl‐2 overexpression and an anti‐Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde‐3‐phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N‐methyl(R)salsolinol

  2001cited by this paper
• Antiapoptotic Properties of Rasagiline, N‐Propargylamine‐1(R)‐aminoindan, and Its Optical (S)‐Isomer, TV1022

  2001cited by this paper
• Proteasomal function is impaired in substantia nigra in Parkinson's disease.

  2001cited by this paper
• Green tea polyphenol (–)‐epigallocatechin‐3‐gallate prevents N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurodegeneration

  2001cited by this paper
• The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

  2000cited by this paper
• TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.

  2000influential reference
• Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa

  2000cited by this paper
• The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity

  2000cited by this paper
• Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase.

  1999cited by this paper
• BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy.

  1999cited by this paper
• Understanding Parkinson's disease.

  1997cited by this paper
• α-Synuclein in Lewy bodies

  1997cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• Antioxidants in tea.

  1997cited by this paper
• Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage.

  1996cited by this paper

• A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A

  2023cites this paper
• The roles of non-coding RNAs in Parkinson’s disease

  2016cites this paper
• The Use of Biomarkers for Prediction and Prevention of Alzheimer’s and Parkinson’s Diseases

  2013cites this paper
• Parkinson's disease: molecular risk factors.

  2012cites this paper
• Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseases

  2011cites this paper
• Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy

  2010influential citation
• Silencing/Overexpressing Selected Genes as a Model of Sporadic Parkinson’s Disease

  2010cites this paper
• Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease

  2009cites this paper
• Modeling sporadic Parkinson's disease by silencing the ubiquitin E3 ligase component, SKP1A.

  2009cites this paper
• A Sporadic Parkinson Disease Model via Silencing of the Ubiquitin-Proteasome/E3 Ligase Component SKP1A*

  2009cites this paper
• Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD.

  2007cites this paper